Competitor Analysis available at PipelineReview Store

Newsletters

Weekly newsletter focused on antibodies, proteins & peptides, gene therapy, RNA and cell therapy, vaccines, biogenerics and related business. It contains brief abstracts of preclinical & clinical studies, regulatory updates and company news of the previous week, but for biologics only. Subscribe Now

Consultancy

Need consultancy on this topic? La Merie SL provides consultancy services to all clients who wish a fully personal, individual, strictly confidential and exclusive collaboration on a specific subject.

Erythropoietin (EPO)

 

Biogenerics & Therapeutic Proteins Overview

ID No.

Product Name

Target / Mechanism of Action

Class of Compound

Company

Product Category

Indication

1st approval

2006 sales (mln)

vs. previous year (%)

134

Aranesp

EPO-R

Rhu darbepoetin alfa

Amgen

Protein

Renal and cancer anemia

 

US$ 4,121 (+ 26 %) source

509

KRN321

EPO-R

Rhu darbepoetin alfa

Kirin

(from Amgen)

Protein

Anemia

2007

2007 sales expectations of Yen 2.4 bln source

330

Procrit / Eprex

EPO-R

Rhu epoetin alfa

Johnson & Johnson

(from Amgen)

Protein

Renal and cancer anemia

 

US$ 3,180 (- 4 %) source

505

Epogen

EPO-R

Rhu epoetin alfa

Amgen

Protein

Renal and cancer anemia

 

US$ 2,511 (+ 2 %) source

506

ESPO

EPO-R

Rhu epoetin alfa

Kirin

(from Amgen)

Protein

Anemia

 

Yen 40.0 bln (- 3.1 %) = US$ 333

source

507

Neo-recormon

EPO-R

Rhu epoetin beta

Roche

Protein

Renal and cancer anemia

 

NeoRecormon: CHF 1,500 (+ 6 %) = US$ 1,210 source

Copmbined epoetin beta sales:

CHF 2,227 (- 1 %) = US$ 1,794

source

508

Epogin

EPO-R

Rhu epoetin beta

Chugai

(Roche)

Protein

Renal and cancer anemia

 

YEN 63.4 bln (- 8.4 %) ) US$ 524 mln source

 

 

 

 

 

 

 

 

 

Total: US$ 11.939 bln